Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
Oncolytics Biotech Inc. reported updated Cohort 4 results from its Phase 1/2 GOBLET study of pelareorep plus atezolizumab in second-line or later squamous cell anal cancer. Median duration of response was approximately 15 months, compared with historical results of 9.5 months for FDA-approved retifanlimab monotherapy in a similar population. Median overall survival had not yet been reached; all responding patients survived beyond 12 months, including multiple patients over 24 months.
Oncolytics plans to explore additional studies with a potential checkpoint-inhibitor partner to support registrational development in anal cancer. The company believes durable responses may support accelerated approval, while overall survival could support full approval, subject to FDA agreement. It may also explore a pelareorep/checkpoint-inhibitor study in HPV-associated head and neck cancer; that combination has not yet been evaluated there. Oncolytics cited receipt of FDA Fast Track Designation.
Oncolytics Biotech Inc. announced it will present a trial-in-progress abstract and e-poster on REO 033 at the European Society for Medical Oncology Congress 2026. REO 033 is a randomized, controlled, open-label study of pelareorep plus FOLFIRI and bevacizumab versus FOLFIRI and bevacizumab for second-line treatment of RAS-mutated, MSS metastatic colorectal cancer after progression on first-line oxaliplatin-based therapy. Thirty patients per arm will be randomized. Objective response rate is the primary endpoint; secondary endpoints include overall survival, progression-free survival, disease control rate, duration of response, safety and tolerability. Recent U.S. Food and Drug Administration interactions provided the opportunity to initiate a pivotal expansion (Part B), which could support an accelerated approval submission based on ORR and a full approval based on PFS.
Oncolytics Biotech Inc. expects to receive the final Pancreatic Cancer Action Network grant payment later this quarter, following completion of certain activities in GOBLET Cohort 5. The company expects final Cohort 4 results in the fourth quarter of 2026 and initial Cohort 5 results in the first half of 2027; Cohort 5 timing could extend as multiple patients continue treatment and follow-up.
Patients remain on treatment and in follow-up in both cohorts. Cohort 4 evaluates pelareorep with atezolizumab in second-line and later squamous cell anal carcinoma; Cohort 5 evaluates pelareorep-based therapy with chemotherapy, with and without atezolizumab, in first-line metastatic pancreatic cancer. Oncolytics said Cohort 4 median overall survival exceeds its expectations, while the full data set is still being processed. Cohort 5 efficacy data, including overall survival and duration of response, continue to mature. The company said each cohort that enrolled the required number of patients met its prespecified efficacy success criteria.
Oncolytics Biotech Inc. (ONCY) reported an intellectual-property update for pelareorep: a method-of-use patent covering its use as an immunotherapy for cancer has issued in several countries, and the corresponding U.S. patent is expected to issue in the near term. Existing manufacturing patent protection extends through 2044; the company expects method-of-use patents, once issued, to protect covered applications into the late 2040s, subject to granted claims, filing dates and jurisdiction-specific rules.
Three patent application families are pending. Oncolytics expects this quarter to convert one pending application into a U.S. application with a request for Track One prioritized examination; the program’s goal is a final disposition within approximately 12 months after prioritized status is granted, but it does not guarantee allowance. Work with an academic partner on modified “next generation” pelareorep is expected to support a composition-of-matter patent with potential protection for up to 20 years from the applicable filing date. Expected enhanced efficacy would require confirmation through further studies.
Oncolytics Biotech Inc. is seeking shareholder votes at its virtual 2026 annual meeting on November 19, 2026, on seven director nominees, ratification of Baker Tilly US, LLP for 2026, an advisory executive-compensation vote, and an advisory vote on how often that compensation vote should occur. Seven directors are to serve after the meeting, down from nine; Angela Holtham and Wayne Pisano are not standing for reelection. A submitted proxy without voting instructions defaults to votes for the nominees, auditor ratification and executive compensation, and a three-year say-on-pay frequency.
Jared Kelly became CEO on June 11, 2025, replacing interim CEO Wayne Pisano. The 2025 summary compensation table reports total compensation of $2,108,512 for Kelly. Oncolytics reported a net loss of $28.759 million in 2025, compared with $22.794 million in 2024. As of September 22, 2026, 131,120,719 common shares were outstanding and entitled to vote.
Oncolytics Biotech Inc. announced that a paper published in Proceedings of the National Academy of Sciences on September 28, 2026, reports preclinical findings on pelareorep in hepatocellular carcinoma. The study described increases in PD-L1 expression, ICOSL levels on tumor cells, and CD8+ T-cell density after pelareorep infection. The company said these changes shifted the tumor microenvironment from immunologically inactive to active and may make tumors susceptible to immune-based therapies.
Pelareorep is investigational, and Oncolytics said liver cancer is not an indication it intends to pursue at this time. The company stated that pelareorep has been administered to over 1,200 patients.
Oncolytics Biotech Inc. reported that substantially all planned sites for Part A of its randomized REO 033 study are activated, with multiple patients on study. Part A is expected to enroll approximately 60 patients across two treatment arms: pelareorep with FOLFIRI and bevacizumab, and FOLFIRI and bevacizumab alone. Objective response rate is the primary endpoint; progression-free survival, overall survival, safety and biomarker analyses are additional endpoints.
The company expects to have sufficient Part A data for an interim clinical update by year-end 2026, based on evaluable patients enrolled by the end of October. It recently aligned with the FDA on the concept for a potential pivotal Part B expansion. Under the proposed strategy, Part B could support a potential accelerated approval submission based on objective response rate, with progression-free survival as the basis for potential full approval. Part A data is expected to inform Part B’s final size and execution.
Oncolytics Biotech Inc. (ONCY) reported that preclinical data show its investigational immunotherapy pelareorep maintained antitumor activity when combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During intensive dosing, pelareorep, the RAS inhibitor, and their combination each reduced tumor growth versus control, with the largest reductions in the RAS inhibitor and combination groups, and no evidence of antagonism between the two therapies.
When pelareorep dosing was reduced to once weekly, its incremental activity became less evident, leading the company to pursue additional preclinical work to optimize dosing schedules and further characterize pelareorep’s contribution to RAS inhibitor combinations. Pelareorep has been given to over 1,200 patients and is being advanced in metastatic gastrointestinal cancers, where it has received FDA Fast Track designation in colorectal, anal, and pancreatic cancer.
Oncolytics Biotech Inc. reported that the U.S. FDA has provided written feedback on the design of a potential pivotal Part B expansion of REO 033, a randomized study of pelareorep in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. The feedback gives what the company views as important alignment on using objective response rate and duration of response to support a potential accelerated approval pathway, with progression-free survival to support full approval. REO 033 was designed with an initial randomized Part A and a potential pivotal Part B. Part A, with 60 patients, will generate the data that inform whether to launch Part B. Based on the FDA’s feedback, Oncolytics plans to begin Part B start-up activities as soon as positive interim Part A data are available and to pursue an End-of-Phase meeting to finalize key elements of the registration program for pelareorep in colorectal cancer.
Oncolytics Biotech Inc. reported a larger net loss as it advanced its immunotherapy pelareorep and expanded corporate activities. For the three and six months ended June 30, 2026, net losses were $9,442 and $18,685 versus $5,277 and $9,988 in 2025, driven by higher research and development and general and administrative expenses. R&D reached $8,814 and G&A $9,846 for the six‑month period as the company launched a randomized Phase 2 second‑line metastatic colorectal cancer trial and prepared potential registrational work in anal cancer. Cash and cash equivalents were $4,115, with operations funded mainly through at‑the‑market equity sales raising $14,385 in net proceeds. Management states that current resources, even with equity distribution capacity, are not sufficient to fund planned operations for 12 months, and discloses substantial doubt about the ability to continue as a going concern, indicating a need for additional financing or strategic arrangements.